Table 2.
Antibody values in the course of disease after diagnosis during the outbreak.
| Antibody | Week |
Total (N = 117) median (IQR) |
Vaccinated (N = 86) median (IQR) |
Non-vaccinated (N = 31) median (IQR) |
P value |
|---|---|---|---|---|---|
| IgM (S/CO) | |||||
| Week 1 | 0.20 (0.05–0.56) | 0.33 (0.11–0.74) | 0.03 (0.02–0.07) | <0.001 | |
| Week 2 | 1.78 (0.86–6.75) | 2.89 (1.30–10.01) | 0.40 (0.18–1.13) | <0.001 | |
| Week 3 | 1.80 (0.93–6.90) | 3.38 (1.05–9.32) | 1.17 (0.37–2.16) | 0.001 | |
| Week 4 | 1.92 (0.71–5.98) | 2.72 (0.83–6.82) | 0.77 (0.21–2.47) | 0.004 | |
| Week 5 | 1.94 (0.63–4.52) | 2.18 (1.35–5.40) | 0.80 (0.31–2.38) | 0.017 | |
| IgG (S/CO) | |||||
| Week 1 | 2.42 (0.10–5.27) | 4.23 (1.80–6.12) | 0.01 (0.00–0.04) | <0.001 | |
| Week 2 | 7.74 (5.72–9.17) | 8.17 (7.36–9.35) | 0.41 (0.11–2.21) | <0.001 | |
| Week 3 | 7.96 (6.81–9.33) | 8.10 (7.27–9.45) | 3.38 (1.62–7.90) | <0.001 | |
| Week 4 | 8.14 (6.98–9.41) | 8.35 (7.71–9.62) | 4.20 (1.93–7.94) | <0.001 | |
| Week 5 | 7.70 (6.56–8.82) | 8.07 (7.51–8.89) | 6.41 (2.98–8.74) | 0.006 |